TABLE 2.
Comparison of Organ and Absorbed and Effective Dose Estimates for CTT1057 Compared with Those of 68Ga-PSMA-11 (13), 18F-DCFPyL (8), and 18F-PSMA-1007 (9)
| Organ | Absorbed dose (mGy/MBq) |
|||
| 18F-CTT1057 (this work) | 68Ga-PSMA-11 (Afshar-Oromieh et al.) | 18F-DCFPyL (Szabo et al.) | 18F-PSMA-1007 (Giesel et al.) | |
| Adrenals | 9.32E-03 | 1.42E-02 | 3.11E-02 | 1.94E-02 |
| Brain | 5.79E-03 | 9.00E-03 | 2.19E-02 | 7.20E-03 |
| Breasts | 5.06E-03 | 8.80E-03 | 4.57E-03 | 8.06E-03 |
| Gallbladder wall | 1.43E-02 | 1.44E-02 | 1.44E-02 | 2.22E-02 |
| Lower large intestine wall | 1.35E-02 | 1.23E-02 | 1.05E-02 | 4.83E-02 |
| Small intestine | 9.72E-03 | 1.63E-02 | 9.13E-03 | 1.56E-02 |
| Stomach wall | 7.47E-03 | 1.20E-02 | 1.16E-02 | 1.42E-02 |
| Upper large intestine wall | 9.08E-03 | 5.40E-02 | 1.67E-02 | 4.08E-02 |
| Heart wall | 1.78E-02 | 1.09E-02 | 1.29E-02 | 2.51E-02 |
| Kidneys | 6.74E-02 | 1.62E-01 | 9.45E-02 | 1.70E-01 |
| Liver | 1.59E-02 | 3.09E-02 | 3.80E-02 | 6.05E-02 |
| Lungs | 1.33E-02 | 1.02E-02 | 1.08E-02 | 1.11E-02 |
| Muscle | 7.44E-03 | 1.05E-02 | 6.32E-03 | 1.00E-02 |
| Pancreas | 9.10E-03 | 1.38E-02 | 2.44E-02 | 1.92E-02 |
| Red marrow | 6.95E-03 | 9.20E-03 | 1.04E-02 | 1.33E-02 |
| Osteogenic cells | 9.10E-03 | 1.42E-02 | 9.58E-03 | 1.55E-02 |
| Skin | 4.94E-03 | 8.85E-02 | 4.05E-03 | 7.30E-03 |
| Spleen | 1.61E-02 | 4.46E-02 | 1.85E-02 | 7.39E-02 |
| Testes | 9.86E-03 | 1.04E-02 | 1.01E-02 | 8.37E-03 |
| Thymus | 6.72E-03 | 9.90E-03 | 5.56E-03 | 9.90E-03 |
| Thyroid | 5.47E-03 | 9.70E-03 | 8.56E-03 | 8.50E-03 |
| Urinary bladder wall | 2.59E-01 | 1.30E-01 | 8.64E-02 | 1.87E-02 |
| Effective dose (mSv/MBq) | 2.28E-02 | 2.36E-02 | 1.39E-02 | 2.20E-02 |